CLINICAL AND SUBCLINICAL CHARACTERISTICS OF THE PATIENTS WITH DENGUE HEMORRHAGIC FEVER THAI NGUYEN

Luong Thu Quynh Nga1,, Duong Van Thanh1, Nguyen Thi Tuyet1
1 Thai Nguyen University of Medicine and Pharmacy

Nội dung chính của bài viết

Tóm tắt

Objectives: Describe clinical and subclinical characteristics of patients with dengue hemorrhagic fever (DHF) in Thai Nguyen.
Subjects and methods: Retrospective study on 43 patients diagnosed with DHF according to the standard of the Ministry of Health in 2019.
Results: The most common age was 35 - ≤ 60, accounting for 25/43 (58.1%), the least common age was ≤ 16 years old (4.6%). The mean of age was 43.6 ± 16.5; Male (55.8%) was higher proportion than female (44.2%). Patients lived in 15/21 wards and 1/11 communes in Thai Nguyen city; 4/6 districts included Phu Binh, Vo Nhai, Dai Tu and Dong Hy. Patients had fever accounted for the highest rate of 100%, followed by bleeding 31/43 (72.1%), abdominal pain or tenderness10/43 (23.2%), vomiting 7/43 (16.3%), diarrhea (9.3%), pleural effusion and acites 4.6%. Patients with hematocrit 35 - 45% accounted for the highest proportion of 21/43 (48.8%); Next, hematocrit > 45% accounted for 20/43 (46.6%). Patients with low platelets 5 - < 50 accounted for the highest
proportion of 22/43 (51.2%), followed by 20/43 (46.5%) of patients with platelets of 50 - < 150 G/L; No patient had platelets < 5 G/L. Patients with AST 40 - < 400 (U/L) accounted for the highest proportion of 35/43 (81.4%), 2/43 (4.6%) patients with AST ≥ 1000 (U/L). Patients with ALT 40 - < 400 (U/L) accounted for the highest proportion in the study 30/43 (69.8%), 1/43 (2.3%) patients had AST ≥ 1000 (U/L). 100% of patients in the study were cured and discharged from the hospital, with no deaths, of which: patients with DHF and DHF with warning signs accounted for the highest rate of 46.6%.

Chi tiết bài viết

Tài liệu tham khảo

1. WHO (2016). Dengue Bulletin. India.
2. N. Sirisena PDN, S. Mahilkar, C. Sharma, J. Jain,S. Sunil (2021). Concurrent dengue infections: Epidemiology & clinical implications. (0971-5916 (Print).
3. WHO (2023). Dengue and severe dengue. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
4. Ministry of Health (2019), "Decision No. 3705/QD-BYT On Promulgating Guidelines for Diagnosis and Treatment of Dengue Hemorrhagic Fever," August 22, 2019".
5. T. Nguyen-Tien, D. C. Do, X. L. Le, et al (2021). Risk factors of dengue fever in an urban area in Vietnam: a case-control study. BMC public health. Apr 7 2021; 21(1):664.
6. WHO (2009). Dengue Guidline for diagnosis, treatment, prevention and control - New edition WHO Library Cataloguing-in-Publication Data.
7. S. Sangkaew, D. Ming, A. Boonyasiri, et al (2021). Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. The Lancet.Infectious diseases. Jul 2021; 21(7):1014-1026.
8. T. Tsheten, A. C. A. Clements, D. J. Gray, R. K. Adhikary, L. Furuya-Kanamori,K. Wangdi (2021). Clinical predictors of severe dengue: a systematic review and meta-analysis. Infectious diseases of poverty. Oct 9 2021; 10(1):123.
9. D. H. Ng, J. G. Wong, T. L. Thein, Y. S. Leo,D. C. Lye (2016). The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue. PloS one. 2016; 11(12):e0167025.